Eczema & Inflammation

Trial Objective

The purpose of this study is to evaluate an investigational medication, INCB018424, in treating eczema, or atopic dermatitis, in children.

Eczema & Inflammation

This topical cream belongs to a new class of medications called phosphate creams. By blocking proteins that are overactive in the skin and make eczema worse, INCB018424 may reduce inflammation. INCB018424 has been safely used in clinical studies on psoriasis, a skin condition that also is characterized by inflammation. Three different strengths of INCB018424 cream are being studied. This study is open-label, which means that the participants and their study doctor will know what strength of cream they are receiving. Participants will apply the cream twice daily.


This trial is active and currently recruiting.

How to Participate

For more information, contact Shirley Palombi at 303.398.1409 or complete the form below.

Who Can Participate

Participants ages 2-17 years old with atopic dermatitis covering 8 to 20% of the body.

Estimated Time Commitment

5 visits over 12 weeks

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Incyte Corporation




Any Gender

Request More Information